SEREVENT
Clinical safety rating: caution
Comprehensive clinical and safety monograph for SEREVENT (SEREVENT).
Selective long-acting beta2-adrenergic receptor agonist; relaxes bronchial smooth muscle by increasing cyclic AMP.
| Metabolism | Extensively metabolized via hydroxylation by CYP3A4; salmeterol is a substrate for CYP3A4. |
| Excretion | Primarily hepatic metabolism via CYP3A4; ~60% excreted in feces as parent drug and metabolites; ~25% in urine as metabolites; negligible (0.5%) unchanged drug in urine. |
| Half-life | Terminal elimination half-life of 5.5 hours (range 3–7 hours). No dose adjustment in renal or hepatic impairment; accumulation can occur in severe hepatic disease, monitor. |
| Protein binding | 96% bound to plasma proteins, primarily albumin; interaction with highly protein-bound drugs unlikely due to high volume of distribution. |
| Volume of Distribution | 7–15 L/kg (mean ~10 L/kg), indicating extensive extravascular binding, mainly to beta-2 receptors and lung tissue; distributes widely beyond plasma. |
| Bioavailability | Inhalation: ~5–10% systemic bioavailability due to large particle deposition and oropharyngeal swallowing; oral absolute bioavailability is <1% due to extensive first-pass metabolism. |
| Onset of Action | Inhalation: 30–60 minutes in asthma, up to 2 hours in COPD; primarily used for maintenance, not acute relief. |
| Duration of Action | 12 hours (twice daily dosing) due to sustained release formulation; effect on FEV1 persists for 12 hours in asthma and COPD; tolerance may develop with regular use. |
50 mcg (2 inhalations) twice daily via inhalation; maximum 100 mcg/day.
| Dosage form | AEROSOL, METERED |
| Renal impairment | No dose adjustment required for renal impairment; specific GFR-based guidelines do not exist. |
| Liver impairment | No specific dose adjustment for Child-Pugh classes; use with caution in severe hepatic impairment. |
| Pediatric use | Children ≥4 years: 50 mcg (2 inhalations) twice daily via inhalation; safety and efficacy not established in children <4 years. |
| Geriatric use | No specific dose adjustment; monitor for excessive beta-adrenergic effects such as tremor or tachycardia. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for SEREVENT (SEREVENT).
| Breastfeeding | Salmeterol is excreted into breast milk in small amounts. The M/P ratio is unknown. Due to the potential for beta-adrenergic effects in the infant, caution is advised. Consider the risk-benefit ratio; if used, monitor the infant for signs of beta-agonist effects such as tachycardia or irritability. |
| Teratogenic Risk | Serevent (salmeterol) is a long-acting beta-2 agonist. In pregnancy, data are limited. Animal studies have shown some adverse effects at high doses, but no well-controlled human studies. The risk of congenital malformations is not considered significant; however, as with all beta-agonists, there is a potential for fetal tachycardia and hypoglycemia if used near term. Use only if clearly needed, balancing maternal benefit against fetal risk. |
■ FDA Black Box Warning
Increased risk of asthma-related death; salmeterol should not be used in patients with asthma without concomitant use of a long-term asthma control medication (e.g., inhaled corticosteroid).
| Serious Effects |
["Status asthmaticus","Patients with asthma without concomitant inhaled corticosteroid therapy","Hypersensitivity to salmeterol or any component"]
| Precautions | ["Increased risk of asthma-related death","Not for acute exacerbations","Paradoxical bronchospasm","Cardiovascular effects (e.g., increased blood pressure, heart rate)","Hypokalemia","Immediate hypersensitivity reactions"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal heart rate, blood pressure, and signs of bronchospasm or adverse effects. In pregnancy, assess fetal heart rate and uterine activity, especially if used for tocolysis (off-label). Monitor for preterm labor symptoms if used frequently. No specific fetal monitoring required beyond routine prenatal care. |
| Fertility Effects | No specific studies have been conducted on the effects of salmeterol on fertility. Animal studies have not shown impairment of fertility at clinically relevant doses. No adverse reproductive effects are anticipated based on the drug's pharmacology. |